Adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers as prognostic factors of early‐stage large‐cell neuroendocrine carcinoma
Abstract Background We investigated whether adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers affected survival of patients with the early stage of large‐cell neuroendocrine cancer. Methods This was a retrospective multicenter study including consecutive patie...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-04-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14287 |
| _version_ | 1828914153275785216 |
|---|---|
| author | Claudio Andreetti Mohsen Ibrahim Antonio Gagliardi Camilla Poggi Giulio Maurizi Domenico Armillotta Valentina Peritone Leonardo Teodonio Erino Angelo Rendina Federico Venuta Marco Anile Giovanni Natale Mario Santini Alfonso Fiorelli |
| author_facet | Claudio Andreetti Mohsen Ibrahim Antonio Gagliardi Camilla Poggi Giulio Maurizi Domenico Armillotta Valentina Peritone Leonardo Teodonio Erino Angelo Rendina Federico Venuta Marco Anile Giovanni Natale Mario Santini Alfonso Fiorelli |
| author_sort | Claudio Andreetti |
| collection | DOAJ |
| description | Abstract Background We investigated whether adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers affected survival of patients with the early stage of large‐cell neuroendocrine cancer. Methods This was a retrospective multicenter study including consecutive patients undergoing resection of node negative large‐cell neuroendocrine carcinoma. Five‐year survival and disease‐free survival rate were evaluated by the Kaplan–Meier method and the log‐rank test in relation to adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers (synaptophysin, chromogranin A, and neuron‐specific enolase). Results Our study population included 117 patients; 47 (40%) of these received adjuvant chemotherapy. Patients treated with adjuvant chemotherapy had better survival (74% vs. 45%, p = 0.002) and disease‐free survival (79% vs. 40%, p = 0.001) in all cases except patients with tumor <20 mm (79.5% vs. 57.4%, p = 0.43). Lobectomy compared to sublobar resection was associated with better survival (67% vs. 0.1%, p < 0.0001) and disease‐free survival (65% vs. 0.1%, p < 0.0001) also in patients with tumor <20 mm (79% vs. 28%, p = 0.001). Patients with triple‐positive neuroendocrine markers had better survival (79% vs. 35%, p = 0.0001) and disease‐free survival (69% vs. 42%, p = 0.0008). Regression analysis showed that tumor size <20 mm, lobectomy, adjuvant chemotherapy, and triple‐positive immunistochemical neuroendocrine markers were significant favorable prognostic factors for survival outcomes. Conclusions Lobectomy seems to be the management of choice in patients with large‐cell neuroendocrine cancer <20 mm while adjuvant chemotherapy should be administered only in patients with tumor >20 mm. |
| first_indexed | 2024-12-13T19:49:10Z |
| format | Article |
| id | doaj.art-145f3d7ab04c42eab1a86eddf44a7b51 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-13T19:49:10Z |
| publishDate | 2022-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-145f3d7ab04c42eab1a86eddf44a7b512022-12-21T23:33:28ZengWileyThoracic Cancer1759-77061759-77142022-04-0113790091210.1111/1759-7714.14287Adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers as prognostic factors of early‐stage large‐cell neuroendocrine carcinomaClaudio Andreetti0Mohsen Ibrahim1Antonio Gagliardi2Camilla Poggi3Giulio Maurizi4Domenico Armillotta5Valentina Peritone6Leonardo Teodonio7Erino Angelo Rendina8Federico Venuta9Marco Anile10Giovanni Natale11Mario Santini12Alfonso Fiorelli13Thoracic Surgery Unit, Sant'Andrea Hospital University of Rome La Sapienza Rome ItalyThoracic Surgery Unit, Sant'Andrea Hospital University of Rome La Sapienza Rome ItalyThoracic Surgery Unit, Sant'Andrea Hospital University of Rome La Sapienza Rome ItalyThoracic Surgery Unit, Policlinico Hospital University of Rome La Sapienza Rome ItalyThoracic Surgery Unit, Sant'Andrea Hospital University of Rome La Sapienza Rome ItalyThoracic Surgery Unit, Sant'Andrea Hospital University of Rome La Sapienza Rome ItalyThoracic Surgery Unit, Sant'Andrea Hospital University of Rome La Sapienza Rome ItalyThoracic Surgery Unit, Sant'Andrea Hospital University of Rome La Sapienza Rome ItalyThoracic Surgery Unit, Sant'Andrea Hospital University of Rome La Sapienza Rome ItalyThoracic Surgery Unit, Policlinico Hospital University of Rome La Sapienza Rome ItalyThoracic Surgery Unit, Policlinico Hospital University of Rome La Sapienza Rome ItalyThoracic Surgery Unit University of Campania Luigi Vanvitelli Naples ItalyThoracic Surgery Unit University of Campania Luigi Vanvitelli Naples ItalyThoracic Surgery Unit University of Campania Luigi Vanvitelli Naples ItalyAbstract Background We investigated whether adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers affected survival of patients with the early stage of large‐cell neuroendocrine cancer. Methods This was a retrospective multicenter study including consecutive patients undergoing resection of node negative large‐cell neuroendocrine carcinoma. Five‐year survival and disease‐free survival rate were evaluated by the Kaplan–Meier method and the log‐rank test in relation to adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers (synaptophysin, chromogranin A, and neuron‐specific enolase). Results Our study population included 117 patients; 47 (40%) of these received adjuvant chemotherapy. Patients treated with adjuvant chemotherapy had better survival (74% vs. 45%, p = 0.002) and disease‐free survival (79% vs. 40%, p = 0.001) in all cases except patients with tumor <20 mm (79.5% vs. 57.4%, p = 0.43). Lobectomy compared to sublobar resection was associated with better survival (67% vs. 0.1%, p < 0.0001) and disease‐free survival (65% vs. 0.1%, p < 0.0001) also in patients with tumor <20 mm (79% vs. 28%, p = 0.001). Patients with triple‐positive neuroendocrine markers had better survival (79% vs. 35%, p = 0.0001) and disease‐free survival (69% vs. 42%, p = 0.0008). Regression analysis showed that tumor size <20 mm, lobectomy, adjuvant chemotherapy, and triple‐positive immunistochemical neuroendocrine markers were significant favorable prognostic factors for survival outcomes. Conclusions Lobectomy seems to be the management of choice in patients with large‐cell neuroendocrine cancer <20 mm while adjuvant chemotherapy should be administered only in patients with tumor >20 mm.https://doi.org/10.1111/1759-7714.14287adjuvant chemotherapyimmunoistochemical neuroendocrine markerslarge‐cell neuroendocrine carcinomalobectomysurgery |
| spellingShingle | Claudio Andreetti Mohsen Ibrahim Antonio Gagliardi Camilla Poggi Giulio Maurizi Domenico Armillotta Valentina Peritone Leonardo Teodonio Erino Angelo Rendina Federico Venuta Marco Anile Giovanni Natale Mario Santini Alfonso Fiorelli Adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers as prognostic factors of early‐stage large‐cell neuroendocrine carcinoma Thoracic Cancer adjuvant chemotherapy immunoistochemical neuroendocrine markers large‐cell neuroendocrine carcinoma lobectomy surgery |
| title | Adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers as prognostic factors of early‐stage large‐cell neuroendocrine carcinoma |
| title_full | Adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers as prognostic factors of early‐stage large‐cell neuroendocrine carcinoma |
| title_fullStr | Adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers as prognostic factors of early‐stage large‐cell neuroendocrine carcinoma |
| title_full_unstemmed | Adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers as prognostic factors of early‐stage large‐cell neuroendocrine carcinoma |
| title_short | Adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers as prognostic factors of early‐stage large‐cell neuroendocrine carcinoma |
| title_sort | adjuvant chemotherapy extent of resection and immunoistochemical neuroendocrine markers as prognostic factors of early stage large cell neuroendocrine carcinoma |
| topic | adjuvant chemotherapy immunoistochemical neuroendocrine markers large‐cell neuroendocrine carcinoma lobectomy surgery |
| url | https://doi.org/10.1111/1759-7714.14287 |
| work_keys_str_mv | AT claudioandreetti adjuvantchemotherapyextentofresectionandimmunoistochemicalneuroendocrinemarkersasprognosticfactorsofearlystagelargecellneuroendocrinecarcinoma AT mohsenibrahim adjuvantchemotherapyextentofresectionandimmunoistochemicalneuroendocrinemarkersasprognosticfactorsofearlystagelargecellneuroendocrinecarcinoma AT antoniogagliardi adjuvantchemotherapyextentofresectionandimmunoistochemicalneuroendocrinemarkersasprognosticfactorsofearlystagelargecellneuroendocrinecarcinoma AT camillapoggi adjuvantchemotherapyextentofresectionandimmunoistochemicalneuroendocrinemarkersasprognosticfactorsofearlystagelargecellneuroendocrinecarcinoma AT giuliomaurizi adjuvantchemotherapyextentofresectionandimmunoistochemicalneuroendocrinemarkersasprognosticfactorsofearlystagelargecellneuroendocrinecarcinoma AT domenicoarmillotta adjuvantchemotherapyextentofresectionandimmunoistochemicalneuroendocrinemarkersasprognosticfactorsofearlystagelargecellneuroendocrinecarcinoma AT valentinaperitone adjuvantchemotherapyextentofresectionandimmunoistochemicalneuroendocrinemarkersasprognosticfactorsofearlystagelargecellneuroendocrinecarcinoma AT leonardoteodonio adjuvantchemotherapyextentofresectionandimmunoistochemicalneuroendocrinemarkersasprognosticfactorsofearlystagelargecellneuroendocrinecarcinoma AT erinoangelorendina adjuvantchemotherapyextentofresectionandimmunoistochemicalneuroendocrinemarkersasprognosticfactorsofearlystagelargecellneuroendocrinecarcinoma AT federicovenuta adjuvantchemotherapyextentofresectionandimmunoistochemicalneuroendocrinemarkersasprognosticfactorsofearlystagelargecellneuroendocrinecarcinoma AT marcoanile adjuvantchemotherapyextentofresectionandimmunoistochemicalneuroendocrinemarkersasprognosticfactorsofearlystagelargecellneuroendocrinecarcinoma AT giovanninatale adjuvantchemotherapyextentofresectionandimmunoistochemicalneuroendocrinemarkersasprognosticfactorsofearlystagelargecellneuroendocrinecarcinoma AT mariosantini adjuvantchemotherapyextentofresectionandimmunoistochemicalneuroendocrinemarkersasprognosticfactorsofearlystagelargecellneuroendocrinecarcinoma AT alfonsofiorelli adjuvantchemotherapyextentofresectionandimmunoistochemicalneuroendocrinemarkersasprognosticfactorsofearlystagelargecellneuroendocrinecarcinoma |